Stem cell transplantation for mantle cell lymphoma: if, when and how?

Kiss, T. L., Mollee, P., Lazarus, H. M. and Lipton, J. H. (2005) Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplantation, 36 8: 655-661. doi:10.1038/sj.bmt.1705080


Author Kiss, T. L.
Mollee, P.
Lazarus, H. M.
Lipton, J. H.
Title Stem cell transplantation for mantle cell lymphoma: if, when and how?
Journal name Bone Marrow Transplantation   Check publisher's open access policy
ISSN 0268-3369
Publication date 2005
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1038/sj.bmt.1705080
Volume 36
Issue 8
Start page 655
End page 661
Total pages 7
Place of publication Basingstoke, England, United Kingdom
Publisher The Nature publishing Group
Language eng
Subject 1103 Clinical Sciences
Abstract Although the prognosis for mantle cell lymphoma (MCL) patients has improved in recent years, the outlook for those with advanced or recurrent disease remains poor. High-dose chemotherapy and autografting performed early in responding patients appears to be a method to extend progression-free survival (PFS) and overall survival (OS). The use of monoclonal antibody therapy added into the initial therapy and in the peritransplant period may improve on these results. Myeloablative allogeneic transplant appears to be a modality capable of providing curative therapy, but is plagued by a high treatment-related mortality, especially in older patients. Reduced-intensity conditioning allografting have fewer problems associated with the initial phase of transplant and hence may be preferred for those patients for whom an allograft is considered but have comorbid conditions or age issues that preclude a full allograft. Long-term results are lacking and the side effects associated with chronic GVHD may be as significant and debilitating. Trials designed to look at newly diagnosed patients with MCL examining the outcomes after planned autologous and allogeneic transplant as part of the initial management are needed to confirm the role of these various modalities in the overall therapy of this poor-outcome lymphoma.
Keyword Mantle cell lymphoma
Autologous
Allogeneic
Nonmyeloablative stem cell transplantation
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Excellence in Research Australia (ERA) - Collection
School of Music Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 12 Jan 2010, 14:28:51 EST by Simon Utteridge on behalf of Faculty Of Health Sciences